Growth factor signaling in epithelial cell plasticity during development and cancer;Rôle des facteurs de croissance dans la plasticité des épithéliums au cours du développement et dans la carcinogenèse

Bulletin de l'Academie Nationale de Medecine

Volumn 185, Issue 7, 2001, Pages 1279-1292

  Thiery, Jean Paul ^a  

^a INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; GROWTH PROMOTOR;

BLADDER TUMOR; CANCER INVASION; CARCINOMA; CELL DIFFERENTIATION; CELL TRANSFORMATION; DISEASE COURSE; EPITHELIUM CELL; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PRENATAL DEVELOPMENT; REVIEW; SIGNAL TRANSDUCTION;

CARCINOMA; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EMBRYONIC AND FETAL DEVELOPMENT; EPITHELIAL CELLS; FIBROBLAST GROWTH FACTORS; GROWTH SUBSTANCES; HUMANS; NEOPLASM INVASIVENESS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 0035750202     PISSN: 00014079     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0001-4079(19)34450-4     Document Type: Article

References (43)

1. ORNITZ D. M., ITOH N. - Fibroblast growth factors. Genome Biol., 2001, 2, 3005.1-3005.12.
2. MASSAGUÉ J., CHEN Y.G. - Controlling TGF-b signaling. Genes Dev., 2000, 14, 627-644.
3. YARDEN Y., SLIWKOWSKI M.X. - Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol., 2001, 3, 127-37.
4. LE DOUARIN N.M., KALCHEIM C. The neural crest. Cambridge University, 1999, 445 p.
5. KELLER R. Early embryonic development of Xcnopus laevis. Methods in cell biology. 1991, 36, 61-113.
6. WARBURTON D., SCHWARZ M., TEFFT D., FLORES-DELGADO G., ANDERSON K.D., CARDOSO W.V. - The molecular basis of lung morphogenesis. Mech. Der., 2000, 92, 55-81.
7. HACOHEN N., KRAMER S., SUTHERLAND D., HIROMI Y., KRASNOW M.A. - Spouty encodes a novel antagonist of FGF signalling that patterns apical branching of the Drosophila airways. Cell. 1998, 92, 253-263.
8. MAILLEUX A., TEFFT J.D., NDIAYE D., NOBUYUKI I., THIERY J.P., WARBURTON D., BELLUSCI S. Evidence that SPROUTY2 functions as an inhibitor of mouse embryonic lung growth and morphogenesis. Mech. Dev. 2001, 102, 81-94.
9. ALLRED C., MEDINA D. - Introduction : Models of premalignant breast disease. Journal of Mammary Gland, Biology and Neoplasia, 2000, 5, 339-340.
10. GUILFORD P.G., HOPKINS J.B.W., GRADY W.M., MARKOWITZ S.D., WILLIS J., LYNCH H., RAJPUT A., WIESNER G.L., LINDOR N.M., BURGART L.J., TORO T.T., LEE D., LIMACHER J.M., SHAW D.W.,FINDLAY M.P.N., REEVE A.E. - E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Human Mutation, 1999, 14, 249-255
11. THIERY J.P., CHOPIN D. Epithelial cell plasticity in development and tumor progression. Cancer Metastasis Rev., 1999, 18, 31-42.
12. BELLUSCI S., MOENS G., GAUDINO G., COMOGLIO P., NAKAMURA T., THIERY J.P., JOUANNEAU J. - Creation of an hepatocyte growth factor/scattor factor autocrine loop in carcinoma cells induces invasive properties associated with increased oncogenic potential. Oncogene, 1994a, 9, 1091-1099.
13. MORALI O.G., DELMAS V., MOORE R., JEANNEY C., THIERY J.P., LARUIE L. - Rapid β-catenin nuclear relocation and E-cadherin degradation during an epithelium to mesenchyme transition induced by IGF-II. Oncogene, 2001, Oncogène, 2001, 20, 4942-4950.
14. MORALI O.G., DELMAS V., MOORE R., JEANNEY C., THIERY J.P., LARUIE L. - Rapid β-catenin nuclear relocation and E-cadherin degradation during an epithelium to mesenchyme transition induced by IGF-II. Oncogene, 2001, Oncogène, 2001, 20, 4942-4950.
15. BOYER B., ROCHE S., DENOYELLE M., THIERY J.P. - Src and ras are involved in separate pathways in epithelial cell scattering. Embo J., 1997, 16, 5904-5913.
16. CANO A., PEREZ-MORENO M.A., RODROGO I., LOCASCIO A., BLANCO M. J., DEL BARRIO M.G., PORTILLO F., NIETO M.A. - The transcription factor Snails controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nature Cell Biol., 2000, 00, 1-8
17. SAVAGNER P., YAMADA K.M., THIERY J.P. The zinc-finger protein Slug causes desmosome dissociation, an initial and necessary step for growth-factor-induced epithelial-mesenchymal transition. J. Cell Biol., 1997, 137, 1403-1419.
18. PETIT V., BOYER B., LENTZ D., TURNER C.E., THIERY J.P., VALLÁS A.M. Phosphorylation of tyrosine residues 31 and 118 of paxillin regulates cell migration through an association with CRK in NBT-II cells. J Cell Biol., 2000, 148, 957-969.
19. JOUANNEAU J., MOENS G., BOURGEOIS Y., POUPON M.F., THIERY J.P. A minority of carcinoma cells producing acidic fibroblast growth factor induces a community effect for tumor progression. Proc. Natl Acad. Sci. USA, 1994, 91, 286-290.
20. JOUANNEAU J., PLOUET J., MOENS G., THIERY J.P. - FGF-2 and FGF-1 expressed in rat bladder carcinoma cells have similar angiogenic potential but different tumorigenic properties in vivo. Oncogene, 1997, 14, 671-676.
21. JOUANNEAU J., MOENS G., THIERY J.P. The community effect in FGF-1 mediated tumor progression of a rat bladder carcinoma does not involve a direct paracrine signaling. Oncogene, 1999, 18, 327-333.
22. LESUEUR F., MESNIL M., DELOUVÉE A., GIRAULT J.M., THIER Y J.P., JOUANNEAU J. Tumorigenesis of NBT-II rat bladder carcinoma cells does not require gap junctional cell-cell communication. Int. J. Cancer, 2001, soumis.
23. BELLUSCI S., MOENS G., DELOUVÉE A., THIERY J.P., JOUANNEAU J. SFL production by carcinoma cells induces the aggressive properties of non-producing cells in vivo via a community effect. Invasion and Metastasis, 1995, 14, 319-328.
24. BELLUSCI S., MOENS G., THIERY J.P., JOUANNEAU J. A scatter factor-like factor is produced by a metastatic variant of a rat bladder carcinoma line. J. Cell Science, 1994b, 107, 1277-1287.
25. GRASSI M., MOENS G., ROUSSELLE P., THIERY J.P., JOUANNEAU J. - The SFL activity secreted by metastatic carcinoma cells is related to laminin 5 and mediates cell scattering in an integrin-independent manner. J. Cell Science, 1999, 112, 2511-2520.
26. OKADA-BAN M., MOENS G., THIERY J.P., JOUANNEAU J. - Nuclear 24kD FGF-2 confers metastatic properties to rat bladder carcinoma in a conventional FGF receptor independant manner. Oncogene, 1999, 18, 6719-6724.
27. NABHOLTZ J.M., SLAMON D. - New adjuvant strategies for breast cancer. Meeting the challenge of integrating chemotherapy and trastuzumab (herceptin). Semin. Oncol., 2001, 1, 1-12.
28. FROST P., HART I., KERBEL K. - Monoclonal antibodies in cancer therapy. Cancer and Metastasis Rev., 1999, 18, 409-490.
29. SYRIGOS K.N., SKINNER D.G. - Bladder cancer. Biology diagnosis and Management, 1999, Oxford University Press, 469 p.
30. GIL-DIEZ DE MEDINA S., CHOPIN D., EL MARJOU A., DELOUVEE A., LA ROCHELLE W.J., HOZNEK A., ABBOU C.C., AARANSON S.A., THIERY J.P., RADVANYI F. - Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas. Oncogene, 1997, 14, 323-330.
31. RAVERY V., GRIGNON D., ANGULO J., PONTES E., MONTIE J., CRISMAN J., CHOPIN D. -Evaluation of epidermal growth factor receptor, transforming growth factor alpa, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. Urol. Res., 1997, 25, 9-17.
32. EL MARJOU A., DELOUVÉE A., THIERY J.P., RADVANYI F. - Involvement of Epidermal Growth Factor Receptor (EGFR) in chemically-induced mouse bladder tumour progression. Carcinogenesis, 2000, 21, 2211-2218.
33. RICOL D., CAPPELLEN D., EL MARJOU A., GIL-DIEZ DE MEDINA S., GIRAULT J-M., FERRY G., TUCKER G., POUPON M-F., CHOPIN D., THIERY J.P., RADVANYI F. - Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene, 1999, 18, 7234-7243.
34. WERNER S., WEINBERG W., LIAO X., PETERS K.G., BLESSING M., YUSPA S.H., WEINER R.L., WILLIAMS L.T. Targeted expression of a dominant-negative FGF receptor mutant in the epidermis of transgenic mice reveals a role of FGF in keratinocyte organization and differentiation. Embo J., 1993, 12, 2635-2643.
35. GIL DIEZ DE MEDINA S., POPOV Z., CHOPIN D.K., SOUTHGATE J., TUCKER G., DELOUVÉE A., THIERY J.P., RADVANYI F. - Relationship between E-cadherin and Fibroblast Growth Factor Receptor 2b expression in bladder carcinomas. Oncogene, 1999, 18, 5722-5726.
36. COLVIN J.S., BOHNE B.A., HARDING G.W., MCEWEN D.G., ORNITZ D.M. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat. Genet., 1996, 12, 390-397.
37. DENG C., WYNSHAW-BORIS A., ZHOU F., KUO A., LEDER P. Fibroblast growth factor receptor 3 is negative regulator of bone growth. Cell, 1996, 84, 911-921.
38. LI C., CHEN L., IWATA T., KITAGAWA M., FU X. Y., DENG C.X. - A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. Hum. Mol. Genet., 1999, 8, 35-44.
39. WANG Y., SPATZ M.K., KANNAN K., HAYK H., AVIVI A., GORIVODSKY M., PINES M., YAYON A., LONAI P., GIVOL D. A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3. Proc. Natl. Acad. Sci. (USA), 1999, 96, 4455-4460.
40. BILLEREY C., CHOPIN D., AUBRIOT-LORTON M-H., RICOL D., GIL DIEZ DE MEDINA S., VAN RHIJN B., BRALET M-P., LEFRÈRE-BELDA M-A., LAHAYE J-B., ABBOU C.C., BONAVENTURE J., ZAFRANI E.S., VAN DER KWAST T., THIERY J.P., RADVANYI F. - Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. American J. Pathol., 2001, American J. Path., 2001, 158, 1955-1959.
41. BILLEREY C., CHOPIN D., AUBRIOT-LORTON M-H., RICOL D., GIL DIEZ DE MEDINA S., VAN RHIJN B., BRALET M-P., LEFRÈRE-BELDA M-A., LAHAYE J-B., ABBOU C.C., BONAVENTURE J., ZAFRANI E.S., VAN DER KWAST T., THIERY J.P., RADVANYI F. - Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. American J. Pathol., 2001, American J. Path., 2001, 158, 1955-1959.
42. CAPPELLEN D., DE OLIVEIRA C., RICOL D., GIL-DIEZ DE MEDINA S., BOURDIN J., SASTRE-GARAU X., CHOPIN D.K., THIERY J.P., RADVANYI F. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet., 1999, 23, 18-20.
43. KAROUI M., HOFMANN-RADVANYI H., ZIMMERMANN U., COUVELARD A., DEGOTT C., FARIDONI-LAURENS L., AHOMADEGBE J-C., GAZZERI S., BRAMBILLA E., CLERICI T., CHARBONNIER P., TRESALLET C., PENNA C., ROUGIER P., BOILEAU C., THIERY J.P., NORDLINGER B., FRANC B., RADVANYI F. No evidence of somatic FGFR3 mutation in various type of carcinoma. Oncogene, 2001, 20, 5059-5061.